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Abstract 
Background: Mucosal healing is becoming a major goal in the treatment of Crohn’s disease. It 
has been previously reported that myeloid cells induce mucosal healing in a mouse model of 
acute colitis. The aim in this study is to investigate the pro-repair function of myeloid cells in 
healthy donors (HD) and Crohn’s disease patients (CD).  
Methods: Peripheral blood mononuclear cells (PBMC) from HD and CD patients were 
isolated from blood samples and tested either directly or after differentiation ex-vivo into 
macrophages (Mφ). Intestinal macrophages (IMACs) were isolated from the bowel mucosa of 
patients undergoing intestinal surgical resections. Through an in vitro wound healing assay 
the repairing ability of these various human myeloid cells and the mechanisms responsible of 
wound healing were evaluated.  
Results: PBMC and myeloid CD14
+
 cells from HD and CD were not able to repair at any 
tested cell concentration. Mφ from HD and ulcerative colitis (UC) patients were able to 
induce wound healing and this capacity was partially mediated by Hepatocyte Growth Factor 
(HGF). Remarkably, CD Mφ were unable to promote wound healing and produced lower 
levels of HGF as compared to Mφ from HD or UC patients. In particular, Mφ from CD in 
active phase (ACD) exhibited the weakest repair function, but this defect was rescued if rh-
GM-CSF was added during the differentiation of PBMCs. Interestingly, IMACs from HD 
promoted wound healing and produced HGF. 
Conclusion: We demonstrated that CD Mφ, unlike HD or UC Mφ, were defective in 
promoting wound healing, in particular if coming from an ACD. This deficient pro-repair 
function was related to a lower production of HGF. IMACs from HD colonic mucosa induced 
wound healing, confirming the results obtained with Mφ. Our results are in keeping with the 
current theory of CD as an innate immunodeficiency. In this context, Mφ may be responsible 
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for the mucosal repair defects observed in CD patients and for the subsequent chronic 
activation of the adaptive immune response. 
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Abbreviations 
 
Ab: Antibody 
A CD: Active Crohn’s Disease 
BSA: Bovine Serum Albumin 
CD: Crohn’s Disease 
CFU: Colony Forming Unit 
DAB: 3,3'-Diaminobenzidine 
DSS: Dextran Sulphate Sodium   
ECs: Epithelial cells 
EDTA: Ethylenediaminetetraacetic acid 
ELISA: Enzyme-Linked Immunosorbent Assay 
FCS: Foetal Calf Serum 
GM-CSF: Granulocyte Macrophage Colony Stimulating Factor   
HD: Healthy Donor 
HGF: Hepatocyte Growth Factor 
HkEc: Heat killed E. coli 
IMACs: Intestinal macrophages 
Mφ: Macrophages 
PBMCs: Peripheral Blood Mononuclear Cells       
PBS: Phosphate Buffer Saline 
PFA: Paraformaldehyde 
P/S: Penicillin/Streptomycin 
R CD: Remission Crohn’s Disease 
UC: Ulcerative Colits    
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Background 
 
Crohn’s disease (CD) is a chronically relapsing inflammatory condition of the gastrointestinal 
tract characterised by transmural segmental inflammation and mucosal ulcers. These features 
can lead to severe complications such as stenoses, fistulas, perforations and bleeding.
1
 As a 
consequence 75-90% of CD patients will eventually need hospitalizations and/or surgical 
interventions. There remain numerous gaps in our knowledge of the immunopathogenetic 
events leading to intestinal inflammation and its consequences. 
Several susceptibility genes have been identified for CD, as CARD15/NOD2, IBD5, IL23R 
and ATG16L1 and recent genome-wide association studies (GWAS) identified more than 60 
gene polymorphisms that increase susceptibility for this disease (Lee and Parkes, Briefing in 
Functional Genomics, 2011), but they failed to contribute to the determination of the 
hereditable risk. 
Many different factors seem to be involved in the CD pathogenesis. The genetic background, 
together with environmental factors including intestinal microflora, smoking habits, infections 
and dietary habits, can lead to abnormal innate and adaptive immune responses directed 
towards the intestinal flora and eventually leading to the destruction of the intestinal mucosa.
2
 
Since there is no cure for CD, the goals of treatment are to induce remission, to maintain it, to 
minimize side effects, and to improve the quality of life. Classical medications for treating 
CD include corticosteroids, antibiotics or immune-modulators
1
. 
In the last few years, after the introduction of biological treatments, there has been increasing 
interest on the impact of mucosal healing (MH) in the outcome of the disease. In particular the 
endoscopic substudy of the ACCENT I clinical trial highlighted the relationship between 
mucosal healing and lower rates of patient hospitalisations
3
. New evidence showed that 
healing of the colonic mucosa was associated with prolonged remission rates, lower rates of 
complications, less need for steroids in the follow-up and fewer surgical interventions
4-6
. 
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Collectively these clinical data suggest that promoting MH should become a new therapeutic 
goal in CD. 
The murine Dextran Sulphate Sodium (DSS) colitis model is considered a very useful tool to 
investigate the mechanisms involved in wound healing and characterize the cell populations 
involved in this process because DSS has a direct toxic effect on intestinal epithelial cells, 
causing erosions and ulcers followed by acute colonic inflammation.7 
In our previous work we provided evidence that GM-CSF (Granulocyte-Macrophage Colony-
Stimulating Factor) promoted mucosal repair, dampened colon inflammation and ameliorated 
the clinical signs of colitis in the DSS colitis model. Remarkably, we observed that GM-CSF-
expanded monocytic CD11b
+
 cells promoted both in vivo and in vitro wound re-
epithelialisation, suggesting that myeloid cells are instrumental in MH
8
. We further 
demonstrated that macrophage-depleted or GM-CSF-receptor-KO (GM-CSFRKO) mice were 
deficient in ulcer healing (manuscript in progress). 
Some authors have hypothesized a role of the innate immune system in the pathogenesis of 
CD, proposing a model of innate immune deficiency
9
. It was demonstrated that CD patients 
have an impaired acute inflammation leading to a defective neutrophil recruitment. This was 
proved in two different models, first evaluating the acute inflammatory response following 
acute trauma in the colonic mucosa
10
 and then after subcutaneous injection of killed 
Escherichia coli in healthy controls or CD patients
11
. This impaired neutrophil accumulation 
may lead to an incomplete removal of bacteria and consequently to increased phagocytosis by 
macrophages (Mφ) with formation of granulomas
9, 10, 12
. Moreover, Mφ derived from CD 
patients and challenged with heat-killed E.coli (HkEc) show diminished production of pro-
inflammatory cytokines
11
. 
Following these data, some authors proposed to stimulate the intestinal innate immunity in 
CD with GM-CSF, a cytokine known to promote myeloid cells growth, differentiation and 
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function, and already known to ameliorate the disease in mice models
 8, 13
. GM-CSF was 
investigated first in an open-label dose-escalation trial on 15 patients with moderate to severe 
CD (CD Activity Index, CDAI, greater than 200 and lower than 475) and the treatment 
resulted in a significant decrease in mean CDAI after 8 weeks of treatment with negligible 
side effects
14
. A larger randomized, placebo-controlled trial was then performed including 124 
patients with CDAI between 200 and 475 and treatment with GM-CSF resulted to an 
increased remission rate, lower median CDAI, improved quality of life and improved mucosal 
healing
15
.  
In the light of these insights, we decided to investigate further the features of myeloid cells 
coming from CD patients, in particular regarding their role in mucosal healing (MH). 
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Materials and Methods 
 
PBMCs isolation and Macrophages differentiation, culture and stimulation 
Peripheral venous blood was collected from patients or healthy donors (HD) in tubes 
containing EDTA. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll 
density gradient centrifugation and then CD14+ cells were positively selected by magnetic 
sorting (Anti-human magnetic particles-DM- Clone MφP9- BD Biosciences). Cells were 
plated at density of 0.5-1x10
6
 cells/well in 12-well plates suspended in RPMI complete 
medium (L-Glutamine, 25mM HEPES, 10% FCS, 1% P/S). At day one and 4, non-adherent 
cells were discarded. At day 5, adherent macrophages (Mφ) were recovered by scraping. 
Where indicated, at day 5, Mφ were activated for 24 h with HkEc with a ratio 1:50 Mφ/CFU.  
Where indicated, HD and CD PBMCs CD14
+
 were cultured for 5 days at 37°C and 5% CO2 
in the presence of 10 ng/ml recombinant-human GM-CSF (rh-GM-CSF) (R&D) or goat anti-
human GM-CSF antibody (R&D) at the concentration of 2 µg/ml. 
 
In vitro wound healing assay (Fig. 1) 
To test the repairing ability of myeloid cells, an in vitro wound healing model was used. 
Human intestinal carcinoma Caco.2 cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% FCS and 1% Penicillin/Streptomycin to confluent 
monolayers in 12 well plates at 37°C and 5% CO2. Caco.2 monolayers were starved for 24 h 
in 0.5% FCS DMEM and then wounded with a p1000 plastic pipette tip connected to a 
vacuum aspirator, to produce reproducible circular wounds with an average size of 0.8-1.4 
mm
2
 
16
. Epithelial cells were then incubated for 3 more days to observe wound healing. As 
negative control we used serum deprived medium (DMEM 0.5% FCS), whereas DMEM 10% 
FCS was our positive control (Fig.1) 
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On day 3, epithelial cell monolayers were fixed for 10 minutes with 4% paraformaldehyde 
(PFA) and stained for 4 min with Groat Haematoxylin. 
Pictures were taken using a 4x objective (microscope Olympus IX81) at day 0 (day of 
wounding) and at day 3 and wounded areas measured using Photoshop software
17
.        
Wound healing was assessed as the percentage of re-reepithelialised area at day 3 as 
compared to day 0. 
To evaluate the wound healing ability of myeloid cells, PBMCs, CD14
+
 or CD14
- 
cells or Mφ 
isolated from CD patients or HD were added at day 0  in different Mφ: Caco.2 ratios (1:5, 
1:10, 1:100) on top of wounded epithelial monolayers18.   
 
 
 
Fig. 1- In vitro wounding assay 
a) Our in vitro model 
b) Representative pictures of wounded monolayers taken at day 0 (upper row) and at day 3 (lower row). The left 
column represents the negative control; the right column is the positive control
 
 
 
Flow cytometric analysis of Mφ 
Mφ were surface-stained with monoclonal antibodies to CD14 (clone M5E2, BD 
Biosciences), CD11b (clone ICRF44, BD Biosciences), CD11c (clone B-ly6, BD 
Biosciences), CD16 (clone 3G8, BD Biosciences), HLA-DR (clone G46-6, BD Biosciences), 
CD33 (clone WM53, BD Biosciences), CX3CR1 (clone 2A9-1, MBL), CD116 (clone 
a) b) 
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hGMCSFR-M1, BD Biosciences), CD68 (clone Y1/82A, BD Biosciences). Data were 
acquired using a FACSscan flow cytometer (BD Biosciences) and analysed with CellQuest 
software (BD Biosciences). Dead cells were excluded by Propidium Iodide staining. 
 
F-actin formation 
To quantify F-actin formation in epithelial cells (ECs), Caco.2 cells, fixed as described above, 
were permeabilized for 10 minutes with 0.3% Triton X-100/PBS, incubated in a blocking 
solution (2% bovine serum albumin/PBS) for 30 minutes at room temperature (RT) and then 
incubated with Alexa Fluor 488 Phalloidin (Invitrogen A12379) for 20 minutes. After 
staining, the cells were washed in PBS and analyzed with a fluorescence microscope 
(Olympus IX81) where digital pictures were taken. The density of Phalloidin staining was 
quantified by Photoshop software. 
 
Cell proliferation assay  
PFA-fixed cells were permeabilized for 10 minutes with 0.2% saponin/PBS, incubated at RT 
in a blocking solution (5% normal goat serum/PBS) for 60 minutes and then incubated with 
mouse-α-human Ki67 (nuclear Ab against the nuclear protein KI-67, clone MM1, 
Novocastra) for 1 hour, followed by washing in PBS and staining with a secondary antibody 
goat-α-mouse Alexa Fluor 488 (Mol. Probes) for 30 minutes. After staining, cells were 
washed in PBS, counterstained with Dapi for 5 minutes and then analyzed with a fluorescence 
microscope where digital pictures were taken. The number of Ki-67 positive cells present 
around the wound edge was quantified by Photoshop software. 
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HGF Enzyme-Linked Immunosorbent Assay (ELISA) 
HGF concentration was determined by Enzyme-Linked Immunosorbent Assay (ELISA) using 
the Duo Set ELISA development system by R&D Systems. Briefly, 100 µl of undiluted 
supernatant was added to wells pre-coated with a mouse anti-human HGF Ab and blocked 
with 1% BSA in PBS. After incubation and washing, the wells were incubated with a 
biotinylated goat anti-human HGF Ab, re-washed and then incubated with streptavidin 
conjugated to horseradish-peroxidase. Finally the substrate solution and then the stop solution 
were added and the optical density was measured at 450 nm. Each sample was tested in 
duplicates. 
 
Immunohistochemistry 
Endoscopic biopsies were recovered, fixed in 10% buffered formalin and embedded in 
paraffin.  Samples were then cut in serial sections of 4µm of thickness and mounted on slides. 
Slides were hydrated, washed and quenched in 3% H2O2/PBS to remove endogenous 
peroxidase. Slides were then washed and incubated in an antigen retrieval solution (sodium 
citrate at pH=6). The primary antibodies were added (rabbit anti-human HGFα, Santa Cruz 
and mouse anti-human CD68, clone PGM-1, Dako) and incubated overnight at 4°C. After 
washing, the secondary Ab (rabbit envision HRP, DAKO) was incubated for 30 minutes at 
RT and after further washing, 3,3'-Diaminobenzidine (DAB kit from Vector) was added to 
reveal HGF. Revelation was stopped by washing with tap water.  
Slides were then washed in PBS and incubated for 30 minutes with the secondary antibody for 
CD68, a goat anti-mouse biotin (Amersham, RPN 1177). After washing, slides were 
incubated for 30 minutes in Streptavidin Alkaline Phosphatase (AP) and, after further 
washing, CD68 was revealed by incubation for 15 minutes with 5-Bromo-4-chloro-3-indolyl 
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phosphate/ nitro blue tetrazolium (BCIP/NBT, Roche). The reaction was stopped with NTMT 
solution (NaCl 5M- Tris 2M- MgCl22M- Tween 20 and distilled H2O).  
Slides were then washed, dehydrated and embedded. Pictures were taken with a microscope 
Eclipse 50i connected to a camera DS-Fi 1. 
This study has been approved by the human research ethics committee (protocol 41/11). 
 
Real-time Quantitative Reverse-transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated using RNeasy Plus Micro kit (Qiagen, Valencia, CA). Sample quality 
was tested on agarose gels and absence of genomic DNA assessed by PCR using primers 
specific for the housekeeping gene ALG-9 (unknown sequence, Qiagen). Total RNA samples 
were then submitted to reverse transcription using the ThermoScript RT-PCR system 
(Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol, and 
oligo-dT as primers. PCR amplification was performed on a MyiQ iCycler (Bio-Rad, 
Hercules, CA) using the iQ SYBR Green Supermix (Bio-Rad). Primers specific for HGF 
(sense: 5´AAAGGACTTCCATTCACTTGC; antisense:5´CGCTCTCCCTTACTCAAGCTA) 
were purchased from Microsynth (Balgach, Switzerland).  Primer pairs designed for 
QuantiTect Primer assays (unknown sequence, Qiagen) were used for quantification of c-Met. 
For each individual sample, mRNA quantification was performed by normalizing the number 
of mRNA copies obtained for the gene of interest per million of mRNA copies obtained for 
ALG-9.  
 
Isolation of intestinal macrophages (IMACs) 
Surgical intestinal specimens were collected and washed with PBS; the mucosa was released 
from the muscular layer and then stirred for 30 minutes in HBSS+DTT to free it from mucus. 
The mucosa was then stirred in Hank's Buffered Salt Solution (HBSS) + EDTA 0.1M at 200 
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rpm at 37°C for 30 minutes. After rinsing, epithelial cells were detached by vortexing and 
vigorous shaking. The mucosa was transferred in DMEM + 10% FCS and kept incubated 
overnight at 4°C. The following day, after washing with PBS, mucosal slices were digested in 
PBS + Ca
2+
 and Mg
2+
 with collagenase (Sigma), hyaluronidase (Sigma) and DNase (Roche) 
and stirred for 60 min at 37°C at 300 rpm. The cell suspension obtained was then poured 
through a strainer and slices were discarded following further vortexing and vigorous shaking 
to extract the highest possible number of cells. Intestinal monocitic cells were isolated by 
Ficoll density gradient centrifugation and CD33
+
 cells were positively selected by magnetic 
sorting (mouse anti-human magnetic micro beads, clone AC104.3E3- Miltenyi Biotec)
19
. 
This study has been approved by the human research ethics committee (protocol 41/11). 
 
Statistical analysis 
Statistical analyses to compare two groups were performed using a two-tailed Mann-Whitney 
test, which doesn’t assume a Gaussian distribution (Graph Pad Prism Software). Comparison 
between several groups to identify a trend was performed by a One-way ANOVA test with 
Trend test as post test. Limit of significance was considered for p<0.05.  
 
 
Patients 
All patients’ baseline characteristics are listed in table 1. 
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CROHN'S DISEASE
Patient Age Sex Status of disease Therapy
1 29 M Remission MTX
2 49 M Remission IFX
3 28 F Remission Steroids
4 58 M Remission NO TP
5 29 M Remission IFX
6 22 M Remission IFX
7 41 F Remission UN
8 35 M Remission IFX
9 14 M Remission IFX
10 62 M Remission IFX
11 31 F Remission IFX
12 40 M Remission IFX
13 40 F Remission IFX
14 46 M Remission IFX
15 45 F Active IFX
16 25 F Active IFX
17 24 F Active IFX
18 45 F Active IFX
19 56 M Active Protocol Neovacs
20 56 M Active Protocol Neovacs 
21 29 M Active UN
22 46 F Active Steroids + Azathioprine
23 46 M Active IFX
24 24 M Active IFX
25 35 M Active UN
26 24 F Active IFX
27 48 F Active IFX+ Antibiotics
28 64 M Active Steroids + MTX
ULCERATIVE COLITIS
29 54 M Remission Mesalasine
30 84 M Remission Mesalazine
31 43 F Remission Mesalazine
32 23 F Remission mercaptopurine
33 62 F Remission NO TP
34 31 F Remission IFX
35 43 M Remission IFX
36 48 M Remission NO TP
37 32 F Remission IFX
38 44 M Remission IFX
39 49 M Remission NO TP
40 21 F Remission IFX
41 47 F Remission Mesalazine
42 26 F Active IFX
43 61 M Active IFX
44 44 M Active IFX
45 34 M Active UN
46 71 F Active NO TP
IFX= infliximab
MTX= Methotrexate
UN= Unknown
Table 1- Patients’ baseline characteristics. 
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Results 
 
1. Role of monocytic cells in wound healing 
 
1.1 Role of PBMC, CD14
+
 or CD14
-
 cells 
Caco.2 monolayers were wounded and total HD PBMCs, CD14+ (marker of monocytes) or 
CD14
-
 cells added on top of wounded epithelial cell monolayers at increasing concentrations 
(5x10
3
, 10
4
, 2.5x10
4
, 10
5
, 5x10
5
).  We found no amelioration in the percentage of repair for 
any concentration of PBMCs, CD14
+
 or CD14
- 
cells
 
added, as compared to controls (Fig.2). 
CD total PBMCs as well as magnetically sorted CD CD14
+
 or CD14
- 
cells, showed no 
difference with HD total PBMCs, CD14
+
 or CD14
- 
cells (data not shown) and we concluded 
that neither HD nor CD PBMCs could improve wound healing. 
 
 
  
 
 
 
 
 
Fig.2- No effect of HD PBMCs on epithelial cell repair with (n=6). 
Each dot represents a single HD tested in separate experiments 
a) HD PBMCs were added at increasing concentration 
b) HD PBMCs were added after magnetic sorting for CD14
+
or CD14
- 
a) 
b) 
**p<0.005 
***p<0.0005 
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1.2 Role of macrophages in wound healing 
  
1.2.1 HD macrophages 
Based on previous results showing defective functionality of CD Mφ in pro-inflammatory 
cytokine production, likely leading to an impaired neutrophil recruitment 
10, 11
, we sought to 
investigate further the role of these cells in our wounding assay. HD CD14+ cells were 
differentiated ex-vivo into Mφ as described in Materials and Methods and then added at 
increasing concentrations (5x10
3
, 10
4
, 5x10
4
, 10
5
) on wounded Caco.2 cells. We observed an 
amelioration of repair if Mφ were added compared to the control and the percentage of 
healing was increased with the number of Mφ (Fig. 3 a-b). 
To extend further our data, HD Mφ were activated with heat- killed E. coli (HkEc) for 24 hrs 
(ratio Mφ:CFU=1:50) before being added to our assay. Active Mφ have specifically increased 
functional activity, like killing of intracellular parasites, tumour cells lysis and maximal 
secretion of inflammatory mediators20.  
To confirm the activation status of the Mφ, a quantitative PCR was performed to investigate 
the mRNA expression level of Interleukin-6 (IL-6) after stimulating the Mφ with HkEc, LPS 
(1µg/ml) or CpG oligodeoxynucleotides (CpG ODN, 5µM). We tested 4 HD for each 
condition and there was a significant increase in IL-6 encoding mRNA copy numbers in HkEc 
(mean=371±28.37) and LPS (mean=138±9.6) activated Mφ as compared to not activated 
(NA) Mφ (mean= 21.65±8.9, p<0.005 and p<0.05, respectively), but there was no increase in 
CpG ODN activated Mφ (mean= 22.9±2.8, p<0.9).  
We then tested in our assay the same patients and the same Mφ concentrations as in Fig.3 in 5 
separate experiments.  Once activated with HkEc, HD Mφ were indeed able to induce wound 
repair even at the lowest concentration of 5x10
3
 compared to our negative control (p<0.005). 
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We decided also to test if other stimuli than HkEc were able to induce the same pro-repair 
activity. 5x10
4
 HD Mφ were incubated with either HkEc as before or LPS (1µg/ml) or CpG 
ODN (5µM) and then their pro-repair function was evaluated in the wounding assay. HkEc 
resulted to be the only effective activator; LPS induced a small amelioration of repair but 
without reaching a statistical significance; CpG ODN had no effect (Fig.3 c). 
From these experiments we concluded that human Mφ are indeed able to promote wound 
healing in our in-vitro model and these cells can better perform if activated with a very strong 
stimulus, like HkEc. 
 
 
 
 
 
Fig.3- Amelioration of repair with HD Mφ (n=5) 
a) HD Mφ were added at increasing concentration. 
Each dot represents a single HD tested in separate 
experiments 
 
b) Representative pictures of wounded monolayers 
taken at day 0 (upper row) and at day 3 (lower row). 
The left column represents the negative control; the 
right column is the experimental condition with 10
5
 
HD Mφ 
 
c) 5x10
4
 HD Mφ (n=4) were stimulated for 24 hrs 
with HkEc, LPS, CpG ODN or not stimulated (NA) 
and then added in the assay. Each dot represents a 
single HD tested in separate experiments.
 
 
a) b) 
c) 
*p<0.05 
**p<0.005 
***p<0.0005 
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1.2.2 CD macrophages 
We then investigated if Mφ isolated from CD patients exhibited the same pro-repair function 
as HD Mφ. CD CD14
+
 cells were isolated from PBMC, differentiated ex-vivo into Mφ and 
then added to our wounding assay at increasing concentrations (5x10
3
, 10
4
, 5x10
4
, 10
5
), as 
previously described. This time we could observe no amelioration of wound healing at any 
concentration tested. In fact, there was a significant difference in the percentage of re-
reepithelialised surface between 10
5
 HD Mφ and 10
5
 CD Mφ (Fig. 4). However, when CD 
Mφ were activated with HkEc, their pro-repair function was restored.  
 
 
 
We then evaluated if there was any relationship between the pro-repair function of CD Mφ 
and the status of the disease. Indeed, we found that Mφ isolated from CD patients in active 
phase had a decreased repair function than those isolated from patients in remission, even 
though neither of these Mφ populations could repair significantly better than the negative 
control (Fig.5). 
 
Fig.4- CD (n=22) Mφ exhibit a deficient 
pro-repair function as compared to HD 
(n=14). 
Each dot represents a single individual 
tested in a separate experiment 
****p<0.0001 
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We wondered if this defective pro-repair function found in CD Mφ was applicable also to Mφ 
isolated from UC patients. Interestingly, UC Mφ were able to promote wound healing in our 
assay significantly better than our negative control and CD Mφ (Fig. 6 a-b). As we detected a 
lower repairing ability for ACD as compared to RCD Mφ, we investigated if this defect was 
also applicable to UC Mφ.  A UC Mφ repaired as well as R UC Mφ and there was no 
difference with R UC or HD Mφ (Fig. 6 c). 
Overall we conclude that CD Mφ exhibit a deficient pro-repair function as compared to HD 
Mφ and this deficiency is more evident if the patient is in the active phase of the disease. On 
the other hand, UC Mφ do not seem to share this lack of pro-repair activity, neither when 
obtained from patients in remission nor when obtained from patients with active disease (Fig. 
6 c). 
 
 
 
 
 
 
 
*p<0.05 
**p<0.005 
***p<0.0005 
****p<0.0001 
 
Fig.5- Mφ from CD patients in acute 
phase (A CD, n=11) exhibit a worse 
repair function than Mφ of CD in 
remission (R CD, n=11). 
Each dot represents a single individual 
tested in a separate experiment 
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Fig.6- UC Mφ are able to induce wound healing 
Each dot represents a single individual tested in a separate experiment 
 
a) UC Mφ (n=7) tested at increasing concentrations 
 
b) UC Mφ (n=10) repair better than CD Mφ (n=22), and as well as HD Mφ (n=14) 
 
c) Comparison of all groups tested: HD (n=14), RCD (n=10), ACD (n=11), RUC (n=7), AUC (n=3) 
 
a) b) 
*p<0.05 
**p<0.005 
***p<0.0005 
****p<0.0001 
 
c) 
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2. Phenotypical characterization of HD and CD Mφ 
 
Having demonstrated a functional difference between HD and CD Mφ, we wondered if this 
was associated with a phenotypical diversity of the two populations. To investigate the 
markers expressed by these cells, we stained them with a panel of myeloid markers (CD14, 
CD11b, CD11c, CD16, HLA-DR, CD33, and CD68), the fractalkine receptor CX3CR1, and 
the GM-CSF receptor CD116 and analysed them by flow cytometry. We tested a total of 9 
CD patients and 6 HDs in 6 separate experiments. CD14 (HD 24%, CD 42%), CD11b (HD 
35%, CD 42%) and HLA-DR (HD 46%, CD 47%) were the highest expressed markers while 
CD16 was the lowest expressed (HD 1%, CD 4%). CD33, CX3CR1 and CD116 were 
expressed at lower percentages by CD Mφ compared to HD (6%, 6% and 13% respectively, 
versus 16%, 15%, 24%), but these differences didn’t reach statistical significance, probably in 
part because of the variability amongst HDs and CDs samples (Fig.7).  
 
 
 
   
 
 
 
 
 
Fig.7- Phenotypical characterization of macrophages  
Mφ from HD (n= 6) and CD (n=9) were compared by flow cytometry. No statistically significant 
difference was found 
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3. Characterization of macrophage-induced epithelial repair in vitro 
 
3.1 Is cell contact between epithelial cells (ECs) and Mφ necessary to promote  
  wound healing ? 
To characterize further the mechanisms through which Mφ exert their healing function, in 
particular to determine if there was need for a cell-cell contact between epithelial cells (ECs) 
and Mφ to trigger repair, we introduced transwells in our assay. In the basolateral chamber 
Caco.2 cells were cultivated and wounded as previously described, while 10
5
 HD Mφ, shown 
in our previous experiments to induce repair most effectively, were added in the apical 
chamber. Interestingly, an amelioration of the repair was observed, as compared to the control 
(Fig 8). We could therefore conclude that cell contact is not necessary in our model to induce 
wound healing, suggesting that soluble factors are involved in this process. 
 
 
 
 
 
 
 
Fig.8 - HD Mφ are able to induce wound healing without contact with ECs 
a) Model of transwell: HD Mφ are added in the upper chamber, while Caco.2 cells lie in the 
lower chamber 
b) HD Mφ (n=4) induce repair without contact with Caco.2 cells 
 Each dot represents a single individual tested in a separate experiment 
*p<0.05 
**p<0.005 
 
a) b) 
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3.2 Role of restitution and proliferation in our model  
An efficient wound repair in the bowel mucosa is essential to insure mucosal integrity in the 
gut. After an injury, the epithelial cells surrounding the wound begin first to migrate towards 
the centre of the denuded area within minutes; this process is called restitution and doesn’t 
involve proliferation. Then cells start to proliferate to replenish the cell pool and eventually 
they mature into differentiated epithelial cells21.  
In the light of these elements, we investigated into whether the wound healing promoted by 
human Mφ observed in our assay was either due to a restitution process, to proliferation or to 
both. 
 
3.2.1 Role of Restitution 
To evaluate restitution, we quantified the formation of the F-actin purse string around the 
wound edge. Indeed, after injury, the epithelial sheet responds by reorganizing his actin 
cytoskeleton into a belt around the wound edge, called purse string. This string pulls the 
surrounding cells towards the centre of the lesion flattening these cells with cytoplasm 
protrusions (lamellae) that extend to cover the denuded area17, 22. To test restitution, Caco.2 
cells were cultivated and wounded as previously described and then 10
5
 HD Mφ were added 
in transwells. At day 3, ECs were stained with Alexa Fluor 488 Phalloidin as described in 
Materials and Methods and the intensity of the phalloidin staining in the purse string was 
quantified. We observed an increase in F-actin expression around the wound edge in the wells 
where Mφ were added, as compared to the negative control and could clearly visualize the 
lamellae protruding towards the centre of the denuded area, lamellae which were absent in the 
negative control wells. We could therefore conclude that restitution takes place in our wound 
healing model (Fig.9 and Fig.10). 
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Fig.9- Relationship between F-actin 
expression and wound healing.  
 
One example out of 3 separate 
experiments is represented 
a) Quantification of F-actin expression 
in the purse string.  
b) Percentage of restitution in the same 
experimental setting  
a) b) 
c) 
Fig.10- F-actin expression with 
immunofluorescent staining 
 
a) Negative control (DMEM 0.5%FCS) 
b) Wounded Caco.2+ 10
5
 Mφ. The 
purse string and the actin cytoskeleton 
are visible (white arrows) 
c) Detail of b) to highlight the formation 
of the lamellae (white arrows) 
***p<0.0005 
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3.2.2 Role of proliferation 
We thought next to determine if proliferation was involved in our experimental setting and if 
it would be induced by HD Mφ.  
Caco.2 cells were cultivated and wounded as previously described and 10
5
 HD Mφ were 
added in transwells.  At day 3 ECs were stained for Ki-67 (Ab against the nuclear protein Ki-
67, expressed in proliferating cells) as described in Materials and Methods, and the numbers 
of Ki-67
+
 cells at the wound border were counted. A total of 5 different HD were tested and 
the results expressed as a relative ratio of the total number of Ki-67
+
 cells present in the 
negative control. There was no significant difference in the number of Ki-67+ cells between 
the negative control and the wells with 10
5
 HD Mφ (mean ratio 1 and 0.8, respectively, p=0.5) 
(Fig 11). 
Overall, we could conclude that, in our model, wound healing mediated by HD Mφ is a 
restitution process with a visible actin purse string and without contribution of proliferation. 
 
   
  
Fig.11- Proliferation at wound hedge with Ki-67 
 
One example out of 5 separate experiments is represented. 
Ki-67
+ 
cells are proliferating cells. 
a) Negative control (DMEM 0.5%FCS) 
b) Wounded Caco.2+ 10
5
 Mφ.  
c) Relative quantification of the number of Ki-67
+ 
cells 
a) 
b) 
c) 
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4. Role of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) 
 
 4.1 Role of GM-CSF on HD Mφ 
In our previous work we provided evidence that GM-CSF therapy promotes mucosal repair, 
dampens colon inflammation and ameliorates the clinical signs of DSS mouse colitis. 
Remarkably, we provided evidence that GM-CSF-expanded monocytic CD11b+ cells can 
promote both in vivo and in vitro epithelial repair
8
. The therapeutic role of GM-CSF has been 
also demonstrated in CD patients and it has been justified on the hypothesis of CD as an 
innate immunodeficiency
14, 15
.  
Therefore we decided to investigate into whether GM-CSF plays a role in macrophage-
induced promotion of wound healing. 
As we have previously demonstrated that HD PBMCs CD14
+
 are not able to induce wound 
healing, we wondered if rh-GM-CSF could promote the repair if added directly in the co-
cultures of wounded ECs + HD PBMCs at day of wounding. 104 and 105 PBMCs CD14+ from 
2 HDs were added in duplicates to the Caco.2 with or without rh-GM-CSF or anti-GM-CSF 
Ab. In our model there was neither amelioration nor inhibition of repair in these conditions. 
For 10
4
 PBMCs CD14
+
 the mean percentage of repair was 75% with PBMCs alone, 76% if 
rh-GM-CSF was added and 73% with anti-GM-CSF Ab, with a p=0.54, p=0.39 and p=0.49 
respectively in comparison with the negative control. For 10
5
 PBMCs CD14
+
 the mean 
percentage of repair was 72% with PBMCs alone, 74% if rh-GM-CSF was added and 82% 
with anti-GM-CSF Ab, with a p=0.40, p=0.57 and p=0.22, respectively in comparison with 
the negative control. In the same set of experiments we also added directly rh-GM-CSF or 
anti-GM-CSF in the culture medium of wounded ECs, as controls to test if GM-CSF has a 
direct effect on Caco.2 cells. We could find neither an amelioration of repair nor a delay in 
healing (p=0.288 and p=0.614, respectively in comparison with the negative control). 
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Considering that GM-CSF is a growth factor influencing the growth, differentiation and 
survival of myeloid cells, we tested whether the incubation of HD CD14
+
 cells with either rh-
GM-CSF or anti-GM-CSF during their differentiation into Mφ, could influence the Mφ ability 
to promote healing. We found that neither rh-GM-CSF (Fig. 12 a) nor anti-GM-CSF (Fig. 12 
b) had an effect on HD Mφ regarding their ability to induce wound repair. 
 
 
 
 
 
 
 
 
4.2 Role of GM-CSF on CD Mφ 
CD Mφ were tested in our wounding assay after differentiation with rh-GM-CSF. We 
couldn’t find any significant difference in the percentage of restitution mediated by Mφ if the 
total number of CD patients (n=8) was considered (Fig 13 a). However, interestingly, when 
we analysed separately patients in active phase and patients in remission, we found an 
amelioration of repair only if Mφ coming from patients in the active phase and differentiated 
Fig.12- Ability of HD Mφ differentiated in presence of rh-GM-CSF (a) or anti-GM-CSF (b) to induce 
wound healing.  
a) No difference in repairing ability is found for 10
5
  HD Mφ (n=8) differentiated or not (NA) with rh-GM-CSF 
b) No difference in repairing ability is found for 10
5
  HD Mφ (n=7) differentiated or not (NA) with anti-GM-
CSF. Goat serum was used as a control. 
Each dot represents a single individual tested in a separate experiment.  
The same set of experiment was performed also for 4x10
4
 and 10
4
 Mφ, and produced similar results. 
*p<0.05 
**p<0.005 
a) b) 
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with rh-GM-CSF, were added in our assay. No amelioration of repair was observed if the 
same number of Mφ coming from patients in remission, even if differentiated with rh-GM-
CSF, was added in our model (Fig.13 b). 
 
        
 
 
 
 
Finally, we evaluated the effect of rh-GM-CSF and anti-GM-CSF added on monocytic cells 
during their differentiation into Mφ, with respect to cell survival. We noted that, if anti-GM-
CSF was added in the culture medium, the percentage of survival of CD14
+
 PBMCs during 
their differentiation in Mφ was significantly lower than controls and the cells had a damaged 
phenotype. On the contrary adding rh-GM-CSF increased survival even though this difference 
didn’t reach a statistical significance, but cells were visibly healthier and with a mature 
phenotype (Fig 14 and 15). 
 
 
Fig.13- Addition of GM-CSF during differentiation of Mφ coming from patients in active phase ameliorates 
their ability to promote wound healing 
a) Percentage of wound repair with 10
5
 Mφ from CD patients (n=8) differentiated (rh-GM-CSF) or not (NA) with GM-
CSF 
b) Percentage of wound repair with 10
5
 Mφ from CD patients in acute phase (A) (n=7) or in remission (R) (n=7) and 
differentiated (rh-GM-CSF) or not (NA) with GM-CSF 
a) b) 
*p<0.05 
**p<0.005 
***p<0.0005 
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Overall we could conclude that GM-CSF has a beneficial effect on myeloid cells, as it 
improves cell survival, and it can rescue the defect in wound repair that we reported for active 
CD Mφ. Anti-GM-CSF, on the other hand, had a negative effect on cell survival but it didn’t 
play any role in the pro-repair function. 
Fig.14- Percentage of survival at day 5 
of Mφ (10
6 
Mφ  per well) differentiated 
or not with anti-GM-CSF (n=7) or rh-
GM-CSF (n=10) 
*p<0.05 
 
Fig.15- Giemsa stained Cytospin preparation 
of day 5 Mφ differentiated with anti-GM-CSF 
or with rh-GM-CSF 
  
a) Control, b) anti-GM-CSF, c) rh-GM-CSF 
a) b) 
c) 
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5. Role of Hepatocyte Growth Factor (HGF) 
 
 5.1 Is HGF implicated in our system? 
We have previously demonstrated that Mφ are able to induce wound closure without cell 
contact, therefore we hypothesized that a soluble factor should be involved in the process.  
From our previous work we observed that an increased expression of mRNA levels encoding 
HGF was timely associated with the GM-CSF-induced promotion of mucosal repair in the 
colon of DSS colitic mice
8
. Remarkably, HGF is known to be one of the soluble factors 
implicated in intestinal epithelial repair
21, 23, 24
. 
Indeed, HGF is a growth factor implicated in the repair and remodelling of the epithelium and 
is known to accelerate restitution
25, 26
. It has also been reported in the literature that, being 
also a pro-angiogenetic factor, HGF is raised in the serum of paediatric IBD patients, as well 
as in the serum and in the inflamed mucosa of UC patients
27
. 
We evaluated first if HGF could promote wound repair when added to wounded Caco.2 cells. 
By adding different concentrations of rh-HGF (50-150-300 pg/ml and 10 ng/ml) in our 
system, we observed a marked amelioration of the restitution if this molecule was added 
compared to controls and the healing improvement was concentration-dependent (Fig 16). 
 
 
Fig.16- Percentage of repair induced by 
different concentrations of rh-HGF 
*p<0.05 
**p<0.005 
***p<0.0005 
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We decided then to evaluate the production of HGF by Caco.2 cells and by Mφ. 
We measured the concentration of HGF in the culture supernatant of the Caco.2 cell alone, of 
HD Mφ alone, and of co-culture wounded ECs + HD Mφ. At day 3 after wounding, Caco.2 
cells could produce HGF and they produced more HGF if wounded (200 pg/ml) compared to 
not wounded (50 pg/ml). The production of HGF was higher in wells with wounded Caco.2 + 
HD Mφ (around 500 pg/ml) compared to not wounded Caco.2 + HD Mφ (300 pg/ml).  
The concentration of HGF was then evaluated in the supernatant of CD Mφ at the end of 
differentiation (day 5 of culture) and compared with that of HD Mφ, but we couldn’t find any 
difference between the two groups. This result was confirmed by both the dosage of protein 
concentration by ELISA and by quantification of mRNA expression by qPCR (Fig.17) 
 Interestingly, when we compared the HGF concentration at day 3 in the supernatant from co-
cultures of wounded Caco+ HD or UC Mφ with the supernatant coming from wounded Caco+ 
CD Mφ, we found a lower concentration of HGF if CD Mφ were added than in the presence 
of HD Mφ or UC Mφ (Fig.18)  
  
       
  Fig.17- HGF production by HD and CD Mφ 
a) HGF levels in supernatants of 10
6
 Mφ at d5 of differentiation from HD (n=8) or CD patients (n=11) 
measured by ELISA 
b) relative HGF mRNA expression of 10
6
 Mφ at d5 of differentiation from HD (n=4) or CD patients 
(n=10) measured by qPCR 
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Overall, we could conclude that HGF can promote wound healing in our model and is 
produced by ECs and Mφ.  Mφ secrete high levels of HGF and there is no difference in HGF 
production between HD and CD Mφ during their differentiation. However, if Mφ are in co-
culture with wounded Caco.2 cells, CD Mφ produce less HGF than HD or UC Mφ. 
The biologically active form of HGF is a heterodimer of a heavy α-chain and a light β-chain, 
resulting from proteolytic cleavage of the precursor. The only known high affinity receptor of 
HGF is c-Met, a trans-membrane receptor with tyrosine kinase activity. It is expressed by 
hematopoietic and epithelial cells as well as hepatocytes, fibroblasts, keratinocytes and 
melanocytes, and it transduces all HGF effects on target cells
25, 28
. 
To better understand which cells are the main producers and which are the target of HGF in 
our system, the mRNA expression of both hgf and c-Met was assessed by qPCR in Caco.2 
cells and Mφ at d5 of differentiation from HD, RCD and ACD. Caco.2 cells expressed both      
c-Met (mean 1.88x10
5
 gene copies) and hgf (mean 6.97x10
5
 gene copies). It was then 
evaluated if the expression of these genes was different between HD Mφ and Mφ from RCD 
or ACD, but we couldn’t find any significant difference between these groups (Fig.19).  
 
Fig.18- HGF levels in supernatants of d3 co-
culture of wounded Caco.2 cells + 10
5
 Mφ from 
HD (n=9), CD (n=13) or UC (n=4) 
*p<0.05 
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Overall, we could conclude that Caco.2 cells express both hgf and its receptor c-Met. These 
two genes are also expressed by HD Mφ as well as CD Mφ, regardless of the status of the 
disease. 
 
 
 
 
  
a) 
Fig.19- mRNA expression of hgf and c-Met in 
Caco.2 cells and Mφ 
a) mRNA expression of c-met and hgf in relation to 
housekeeping gene ALG9 in Caco.2 cells 
b) mRNA expression of hgf in Mφ at d5 of 
differentiation from HDs or from RCD or ACD (n=5) 
c) mRNA expression of c-Met in Mφ at d5 of 
differentiation from HDs or from RCD or ACD (n=5) 
 
 
b) 
c) 
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5.2 Inhibition of HGF 
So far we have demonstrated that HGF is able to induce repair of Caco.2 per se and it is 
produced by both epithelial cells and Mφ. Hgf and its receptor c-Met are expressed by both 
Caco.2 cells and Mφ from either HDs or CD patients. Importantly, CD Mφ produce less HGF 
than HD Mφ at d3 of co-culture with wounded epithelial cells.  
Therefore, we concluded that HGF is implicated in wound healing in our system, but we 
couldn’t define yet if HGF was the main factor implicated in the Mφ pro-repair activity. 
To test this hypothesis we evaluated the percentage of repair of wounded Caco.2 cells in the 
presence of an inhibitor of HGF activity. In particular we used a small molecule called 
PHA665752 (Tocris Biosciences), which competitively inhibits binding of ATP to the 
tyrosine kinase domain of c-Met. This molecule in vitro inhibits c-Met dependent phenotypes 
such as cell growth, motility, invasion and morphology, as well as phosphorylation of 
downstream signal transducers. In vivo it exhibits a dose-dependent antitumor activity in a 
gastric carcinoma xenograft model 29, 30. 
We tested first if PHA665752 was able to inhibit HGF-induced wound healing in our model. 
PHA665752 was tested at 200, 400 and 600 nM for a constant HGF concentration of 10 ng/ml 
and a significant inhibition of wound healing was observed only for the highest concentration 
of PHA665752 tested (Fig. 20). 
Next we evaluated if the pro-repair activity of Mφ was inhibited by PHA665752. 10
5
 HD Mφ 
were added in our system on wounded Caco.2 cells with or without addition of PHA665752 at 
600 nM on day of wounding. At day 3 it was observed a partial but significantly lower 
percentage of repair if the c-Met inhibitor was added in the co-culture (Fig. 21). 
Overall we could conclude that HGF is one of the main molecules involved in the pro-repair 
activity mediated by Mφ, as its inhibition leads to a decrease of the percentage of epithelial 
cell repair.  
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5.3 Co-localization of Mφ and HGF in biopsies 
Given that HGF was found to have a pivotal role in the Mφ pro-repair activity in our in vitro 
system, we wondered if it was possible to show a co-localization of HGF and Mφ in human 
intestinal tissue.  
Fig.20- Inhibitory effect on wound 
healing of c-Met inhibitor PHA665752 
 
This figure includes data from 4 separate 
experiments. Dimethyl sulfoxide (DMSO) 
was used as control as PHA is reconstituted 
in DMSO. 
*p<0.05 
**p<0.005 
 
Fig.21- Inhibitory effect on the HD 
Mφ (n=7) pro-repair activity of c-Met 
inhibitor PHA665752 
 
Each dot represents a single individual 
tested in a separate experiment 
 
 **p<0.005 
***p<0.0005 
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Colonic biopsies from control patients were obtained from the CHUV Endoscopy 
Department, fixed in 10% buffered formalin and embedded in paraffin.  Samples were then 
cut in serial sections of 4µm of thickness and enzymatically stained for CD68 (Mφ) and HGF. 
Tissue localization of CD68 was demonstrated in the same area as HGF, in particular in the 
instertitial tissue around the crypts (Fig. 22) 
       
  
 
 
Fig.22- CD68 and HGF expression in serial sections of colonic biopsies from HD 
a) CD68 at 10x magnification (scale bar 100 µm)  b) HGF at 10x magnification   
c) Double staining CD68-HGF 10x magnification      d) Negative control at 10x magnification 
e) CD68 at 40x magnification (scale bar 10 µm), white arrows pointing at positive cells   
b) HGF at 40x magnification (scale bar 10 µm), white arrows pointing at positive cells   
 
c) 
a) b) 
d) 
e) f) 
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6. Role of intestinal macrophages (IMACs) in wound healing 
 
6.1 Role of IMACs in wound healing 
Intestinal macrophages represent the largest population of mononuclear phagocytes in the 
body and are strategically located in the subepithelial lamina propria. These cells have a 
double role of protecting the host against harmful pathogens breaching the epithelium and 
regulating the inflammatory response towards commensal gut microbiota. Thus, in a non 
inflamed mucosa, IMACs acquire inflammatory anergy with downregulation of innate 
response receptors, despite retaining a phagocytic and bactericidal activity
31-33
. 
IMACs have great phenotypical difference from in vitro differentiated Mφ as the classical 
monocyte markers CD14, CD16, CD11b are almost absent. CD33 was identified to be a 
useful recognition marker for IMACs
19
. 
We have previously demonstrated that HD Mφ differentiated ex-vivo from CD14
+
 PBMCs 
exhibit a pro-repair function that is deficient in CD Mφ. We decided to investigate if the same 
pro-repair activity was also characteristic of IMACs. Specimens of healthy colonic mucosa 
were recovered from patients undergoing surgery for colon carcinoma and IMACs were 
isolated as described in Materials and Methods. 10
5 
IMACs, which was the concentration 
inducing the highest percentage of repair for Mφ, were added in our wounding assay. 
Interestingly, a significant amelioration of repair was observed (Fig.23). 
 
Fig.23- Amelioration of repair with HD 
IMACs (n=7)  
 
Each dot represents a single HD tested in 
separate experiments 
*p<0.05 
***p<0.0005 
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Next we examined if IMACs coming from CD patients could induce the same level of repair. 
Due to an extreme difficulty in recruiting ACD in need of a surgical intervention, we 
unfortunately got hold of one single patient who had a severe ileal inflammation. The surgical 
specimen included both the terminal ileum and part of the caecum, which was free from 
inflammation. IMACs were isolated from both sites and tested in our assay. Interestingly, 
colonic IMACs showed a capacity to induce repair, while the ileal IMACs lacked of this 
ability (Fig 24) 
 
 
 
 
 
6.2 HGF production by IMACs and its inhibition 
We have demonstrated that IMACs isolated from HD are able to promote wound healing, 
confirming the results obtained with Mφ. We wondered if IMACs, like Mφ, promoted their 
repair through HGF production.  
First the capacity of HD IMACs to produce HGF was evaluated. The concentration of HGF 
was measured by ELISA at day 3 in the supernatant from co-cultures of wounded Caco + HD 
Fig.24- CD IMACs coming from inflamed ileum cannot induce wound healing  
a) CD IMACs from non-inflamed colon can induce repair, while those from inflamed ileum cannot. 
In this experiment each dot represents a single wound.    
b) Preliminary comparison between HD IMACs, non-inflamed colon CD IMACs, inflamed ileum 
CD IMACs. 
a) b) 
*p<0.05 
**p<0.005 
***p<0.0005 
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IMACs and we found that HD IMACs could produce HGF, like HD Mφ (Fig. 25) 
Next we evaluated if HD IMACs’ pro-repair activity was inhibited by PHA665752. 10
5
 HD 
IMACs were added in our system on wounded Caco.2 cells with or without addition of 
PHA665752 at 600 nM on the day of wounding. At day 3, preliminary data with 3 HD 
IMACs demonstrated a partial but significantly lower percentage of repair if the c-Met 
inhibitor was added in the co-culture (Fig. 26). 
Overall we could conclude that HGF is one of the main molecules involved in the pro-repair 
activity mediated by IMACs, confirming that IMACs and Mφ in our model induce wound 
healing through the same mechanism. 
 
 
Fig.26- Inhibitory effect on the HD 
IMACs (n=3) pro-repair activity of c-Met 
inhibitor PHA665752 
 
Fig.25- HGF levels in supernatants of d3 
co-culture of wounded Caco.2 cells + 10
5
 HD 
IMACs (n=5) 
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Discussion and Conclusion 
 
In our work we focused our attention on the analysis of the role played by Mφ in wound 
healing. The rationale of our choice lies within two main reasons. First, it has been suggested 
that a deficiency in the innate immunity during the acute phase of the inflammation in CD 
patients plays an important role in the evolution of the disease10, 11.  Secondly, our previous 
results in mice studies pointed out a fundamental role of GM-CSF-expanded CD11b
+
 
monocytic cells in inducing wound healing both in vivo and in vitro
8
. Mucosal healing has 
become one of the main targets in clinical studies, as it is associated with a better outcome of 
the disease. Breaches in the gut mucosa, even if minimal, induce a massive penetration of 
bacteria and foreign material through the bowel wall and the necessity to mount an 
appropriate acute response with an immediate repair of the lesion is crucial to control 
bacterial translocation. 
In this work, an in vitro wound healing model has been set-up to investigate the repair 
function of myeloid cells. In this model we demonstrate that PBMCs are inefficient in 
promoting epithelial restitution. In contrast, HD PBMC-derived Mφ acquire this capacity. 
Most interestingly, CD Mφ exhibit a deficient pro-repair function compared to HD or UC 
Mφ, even though these cells are not phenotypically different. In particular there is an 
association between the capacity to repair and the status of the disease, as ACD Mφ have the 
weakest repair function. This deficient function for A CD Mφ can be rescued by adding rh-
GM-CSF during the differentiation of PBMCs in Mφ. We also demonstrate that HD Mφ 
promote wound healing through HGF production. Indeed Mφ produce HGF and the inhibition 
of the HGF receptor c-Met leads to a decreased percentage of repair. Importantly, CD Mφ 
produce less HGF than HD or UC Mφ if in co-culture with wounded epithelial cells. In this 
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work it is also demonstrated that HD IMACs, as blood-derived Mφ, promote wound healing 
through HGF production. 
The fact that PBMCs need to be differentiated in Mφ to promote wound healing indicates that 
acquisition of repair function requires a maturation step presumably taking place in vivo in the 
gut mucosa. In fact HD IMACs are able to induce wound healing.  
Our results indicate that acquisition of the maximal repair function necessitates strong Mφ 
activation as obtained with HkEc, and that both HD and CD Mφ are able to respond to this 
microbial stimulus by increasing their repair function. Hence, impairment of repair activity in 
CD Mφ does not appear as an intrinsic defect in a pro-repair pathway.  
On the other hand, the fact that A CD Mφ are weaker repair cells than R CD Mφ, combined to 
the fact that A CD Mφ can be slightly boosted by rh-GM-CSF during differentiation in 
contrast to R CD Mφ, supports the interpretation that A and R CD have distinct circulating 
myeloid cell populations
34
. Differential repair activities might also be the consequence of 
differential responses to the local environment that strongly differs between HD, A CD and R 
CD. Mφ are a very heterogeneous population influenced by both innate and adaptive signals 
and the cytokine milieu is fundamental in determining Mφ function
20
. 
Interestingly, UC Mφ are able to induce repair regardless of the status of the disease. This 
result suggests that the defect in wound healing observed for CD patients is actually specific 
for the disease and it is not a consequence of an indiscriminate inflammation of the bowel. 
Moreover, these findings are in keeping with the different histological and clinical picture of 
these two forms of IBD. In fact CD patients often present with transmural ulceration and 
fistulising disease, while in UC the inflammation is limited to the mucosa and fistulae are 
rare. It can be speculated that the lack of repairing abilities of CD Mφ is responsible of the 
phenotype observed in patients. 
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From our data it emerges also that soluble factors are involved in the repair process, as Mφ 
don’t need cell contact to promote restitution. Many growth factors are known to be 
implicated in wound healing, such as Transforming Growth Factor- α (TGF-α), TGF-β, 
Keratinocyte Growth Factor (KGF), Epidermal Growth Factor (EGF), Insulin-like Growth 
Factor (IGF) and Hepatocyte Growth Factor (HGF) among others
23, 35, 36
. We decided to focus 
our attention in particular on the role played by HGF, as HGF ameliorates epithelial 
regeneration in both DSS and 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis models
37, 38
 
and HGF deficient mice exhibit impaired intestinal mucosal regeneration
39
. Moreover, HGF 
level was found to be increased in the serum of IBD patients
27
. In our previous work an 
increased expression of mRNA levels encoding HGF was timely associated with the GM-
CSF-induced promotion of mucosal repair in the colon of DSS colitic mice
8
. In relation with 
these results obtained in the mouse model, HGF was found to play a pivotal role in the HD 
Mφ-induced restitution. We demonstrate that HGF is indeed a pro-repair molecule in our 
system and that it is produced at higher levels by HD Mφ than by CD Mφ at day 3 of co-
culture with wounded epithelial cells. This finding establishes a link between HGF production 
by Mφ and restitution rate. However, this difference in HGF secretion is not present if the 
HGF level is measured at the end of Mφ differentiation, implying that the defective HGF 
secretion of CD Mφ is not at the level of gene transcription. This hypothesis is confirmed by 
our PCR data, showing no difference in the mRNA expression of both hgf and its receptor    
c-met in HD and CD Mφ. 
The fact that CD Mφ do not secrete HGF as well as HD Mφ during the co-culture with 
wounded epithelial cells could be explained either by an incapacity of CD Mφ to respond 
adequately to danger signals or by an inefficient release of the molecule. This last hypothesis 
is supported by evidences in the literature demonstrating that HGF is stored in his inactive 
form (pro-HGF) in secretory vesicles and granules of polymorhonuclear cells (PMN), 
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providing a readily available stock
40
. It is therefore conceivable that, if Mφ stock HGF in 
vesicles as PMN do, during a tissue injury, Mφ can rapidly provide high concentration of 
HGF, promoting wound healing. CD Mφ could be deficient in this phase of rapid release. 
Segal’s group provided indeed evidence that CD Mφ are deficient in secretion of pro-
inflammatory cytokines and that this defect is not at the level of gene transcription. On further 
analysis of Mφ mRNA transcription profiles, it was identified a group of abnormally 
expressed genes in CD Mφ and half of them had associations with cellular secretory 
systems
11
. These results are even more intriguing given the known association of variants of 
autophagy genes with CD susceptibility and, importantly, this association was not found in 
UC patients
41
. A defect in autophagy means both an impaired vesicle trafficking and a 
dysfunction to remove intracellular organisms in Mφ, further supporting the hypothesis of Mφ 
deficiencies in CD patients. To test if CD Mφ secrete less HGF due to a release defect, it 
would be first necessary to confirm that HGF is indeed stored intracellularly and then 
compare HD with CD Mφ. This result can be achieved by a simple immunocytochemical 
staining for HGF, by an intracellular FACS analysis for HGF or by a western blot analysis of 
the different Mφ subcellular fractions. Once confirmed that HGF is indeed stored at 
intracellular level, it would be interesting to analyse the secretory capacity of CD Mφ. HGF 
level could be evaluated in the culture medium of HD and CD Mφ after inducing release with 
HkEc/LPS
42
. Lastly, a normal HGF synthesis together with reduced secretion could also mean 
an increased degradation of the molecule. It would be then interesting to check the 
functionality of the lysosomal compartment by adding lysosomal inhibitors (e.g. NH4Cl or 
chloroquine, which increase lysosomal pH) to CD Mφ and then measuring the intracellular 
levels of HGF. If the defect is indeed a hyper-functionality of the lysosomal compartment, the 
HGF intracellular level in CD Mφ after treatment with lysosome inhibitors would increase to 
the same levels of HD Mφ. 
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Another hypothesis explaining the lack of CD Mφ secretion of HGF would be a defective 
response to danger signals, known as damage-associated molecular pattern (DAMPs). A 
DAMP is any molecule not normally exposed that is revealed because of a damage or 
injury
43
. These molecules include high mobility group box-1 (HMGB1), S100A8 (MRP8, 
calgranulin A), S100A9 (MRP14, calgranulin B), and heat shock protein 70 (HSP70). In 
particular HMGB1 is a nuclear protein known to be released passively by necrotic cells and 
actively secreted by immune cells, including Mφ, and enterocytes
44-46
. Its signalling is 
mediated by the receptor for advanced glycation end products (RAGE) and members of Toll-
like family receptors. RAGE is expressed at low levels in normal tissues, it is upregulated at 
sites where its ligands accumulate and it is expressed by monocytic cells among others
46, 47
. 
The interaction of HMGB1 with its receptor RAGE mediates both pro-inflammatory and 
restorative effects. For instance monocytes stimulated with HMGB1 release numerous pro-
inflammatory cytokines
48
, and it is also demonstrated that myofibroblasts stimulated by 
HMGB1 migrate towards damaged regions promoting repair49. Given this evidence, it could 
be hypothesized that CD Mφ are deficient in recognizing DAMPs, as HMGB1, and therefore 
secrete less HGF to induce wound healing. It would be interesting to test this hypothesis by 
incubating HD and CD Mφ with HMGB1 and then test their respective repair capacity, or by 
analysing the expression of the HMGB1 receptor RAGE on the surface of HD and CD Mφ to 
rule out a downregulation of RAGE in CD Mφ. Given that HMGB1 is actively secreted by 
Mφ, it could also be postulated that this molecule works in an autocrine manner. 
Consequently another possibility would be that CD Mφ cannot secrete an adequate amount of 
HMGB1 to induce an auto-stimulation of the Mφ, eventually leading to HGF secretion. To 
investigate this aspect, HD and CD Mφ could be stimulated in vitro with pro-inflammatory 
cytokines and then the level of HMGB1 in the culture medium evaluated. 
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The importance of HGF role in our system was demonstrated by a specific inhibition of HGF 
with PHA665752, which competitively inhibits binding of ATP to the tyrosine kinase domain 
of c-Met. This molecule was found to be more than 50 times more selective for c-Met 
compared with a panel of other tyrosine and serine-threonine kinases
30
. Indeed, the percentage 
of HD Mφ-induced wound healing was significantly lower if PHA665752 was added in our 
system. This result demonstrates that HGF is one of the major factors involved in the Mφ 
mediated pro-repair activity.  
In our work we also demonstrate a co-localization of HGF and Mφ in the lamina propria of 
human colonic biopsies, suggesting that Mφ could be a HGF source also in vivo. 
Unfortunately, technical issues, namely the autofluorescence of human colonic tissue, didn’t 
allow us to proceed with more precise techniques (i.e. immuno-fluorescent staining), which 
would have allowed us to demonstrate the presence of HGF and Mφ markers in the same 
cells.  
Initially, our results have investigated the repair function of in vitro derived Mφ. However, it 
is established that both monocytes and in vitro derived Mφ are phenotypically and 
functionally different from intestinal macrophages (IMACs) 
19, 31-33
. Therefore we decided to 
investigate the pro-repair function of IMACs isolated from the healthy intestinal mucosa of 
patients undergoing surgery for a colon carcinoma. These IMACs were able to induce repair, 
to produce HGF, and PHA665752 inhibited their activity, confirming the results obtained 
with HD Mφ. IMACs are undoubtedly a good tool to investigate the healing function of 
macrophages, being the cells actually present in the mucosa. It has however to be considered 
that surgical specimens are not easy to collect. Moreover the IMACs isolation procedure 
includes enzymatic digestions and mechanical separations that can compromise cell 
functionality. On the opposite, blood samples are readily available and blood-derived Mφ 
have been widely used in the literature to study characteristic of intestinal macrophages
10, 11
.  
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Our aim was to compare the wound healing function of HD IMACs with IMACs from CD 
patients, but, due to the extremely low number of surgeries for CD, we obtained a single 
patient only. These very preliminary data are nevertheless very intriguing, as CD IMACs from 
non-inflamed caecum were able to induce healing, while CD IMACs from inflamed ileum 
could not. To confirm these data we would need first of all to demonstrate that HD IMACs 
from ileal mucosa can induce repair, as so far we have tested HD colonic IMACs only. Some 
evidence identified differences between ileal and colonic macrophages in non inflamed 
mucosa. Normal colonic macrophages were larger and more strongly positive for acid 
phosphatase and non-specific esterase than macrophages in terminal ileum
50
. However there 
was no difference between ileal and colonic macrophages in their ability to undergo a 
respiratory burst
51
. In future studies we would need to accumulate more CD IMACs from both 
colonic and ileal sites and compare them with corresponding HD IMACs. If indeed the ability 
to induce repair is not dependent on the site of macrophage-extraction, it could be speculated 
that is then the cytokine environment responsible to modulate IMACs phenotype and 
functionality. It is reasonable to imagine that in a severely inflamed mucosa, as to necessitate 
a surgical intervention, the IMACs would shift to a more pro-inflammatory macrophage 
phenotype. It has already been demonstrated that in CD there is an increased recruitment of 
blood-derived CD14
+
 monocytes in the mucosa, with upregulation of co-stimulatory 
molecules (CD80 and CD 86) and TREM-1
52-54
.  It would be interesting to test the pro repair 
ability of IMACs at the very beginning of the acute phase of the inflammation. A lack of 
healing capacity would support the hypothesis of an innate immunodeficiency in CD.  
What we have observed so far is that in vitro generated CD Mφ, and in particular ACD Mφ, 
cannot repair as well as HD Mφ. This defect seems to be related to a lower production of 
HGF in an acute situation (i.e. the contact with a wounded epithelial layer). It can be 
speculated that at the very early stage of the acute phase, when the first breaches in the 
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mucosa appear and foreign material start penetrating through the bowel wall, CD resident 
macrophages are unable to promptly react to the new acute situation. Segal et al. 
demonstrated that CD macrophages have a weak inflammatory response, with low pro-
inflammatory cytokine production, likely leading to low neutrophil recruitment and 
consequent impaired bacterial clearance
10
. We could add that CD macrophages are also 
deficient in promoting a rapid mucosal healing, probably due to incapacity to secrete adequate 
amounts of HGF. This slow repair of the mucosa causes an even wider penetration of 
microorganisms,
 
which will eventually lead to the activation of an adaptive immune response 
and a chronic inflammation.  
Given the observed important role of HGF in inducing wound repair, it could be tempting to 
propose HGF as a potential therapy for Crohn’s disease, especially in light of the increasing 
importance of inducing mucosal healing in CD patients. Some issues are nevertheless to be 
taken into account before proposing HGF in a clinical trial. First, HGF is a pro-angiogenetic 
and an epithelial growth factor, therefore potentially increasing the risk of neoplastic 
transformation. Administration of HGF intraperitoneally in a rat model of IBD induced an 
amelioration of the disease and reduced ulceration score without increasing epithelial mitotic 
rate
55
. A preliminary double-blind, placebo-controlled study was performed to investigate the 
potential therapeutic role of Growth Hormone (GH) in CD. The study demonstrated an 
amelioration in the CDAI after four months of treatment and there was no evidence of an 
increase in cancer development (two patients out of 15 in GH group were diagnosed with 
cancer following investigations for symptoms already present before being included in the 
study)
56
.  Despite these encouraging results, a cautious approach is required in particular in 
the context of a chronic disease which usually requires long and repeated cycles of therapy. 
Secondly, the route of HGF administration should be chosen carefully. Intravenous 
administration lacks a precise targeting of ulcerated regions while a topical administration 
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would be preferable, through enemas, suppositories or endoscopically administered injections. 
A Japanese group recently demonstrated a significant repair of injured rectal mucosa in rat 
experimental colitis treated with HGF rectal enemas
57
. 
Our results also support the theory of CD as an innate immune-deficiency. If future evidence 
confirms this hypothesis, it may be interesting to consider a therapy aiming at the stimulation 
of the innate acute response or promoting the bone-marrow production of pro-repair myeloid 
precursors. 
In conclusion, despite being aware that our results are based on in vitro experiments, we were 
able to detect a deficient function in CD Mφ to promote wound healing that, to our 
knowledge, has never been reported before. Our data are in keeping with the current tendency 
in the literature of considering CD as an innate immune-deficiency. We believe that more 
investigations in this direction would contribute to elucidate further the pathogenesis of 
Crohn’s disease and possibly would lead to a reassessment and an improvement of current 
treatment options. 
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